SYNLAB AG |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 10.42 EUR | -0.38% |
|
+1.36% | -8.68% |
| Apr. 22 | Synlab Faces Cyber Attack in Italy | MT |
| Apr. 21 | Dpa-AFX Overview: COMPANIES - The most important news from the weekend | DP |
Strengths
- The company's share price in relation to its net book value makes it look relatively cheap.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
Weaknesses
- The company's earnings growth outlook lacks momentum and is a weakness.
- The company is in debt and has limited leeway for investment
- With an expected P/E ratio at 25.61 and 33.87 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
- The company is not the most generous with respect to shareholders' compensation.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last few months, analysts have been revising downwards their earnings forecast.
- The overall consensus opinion of analysts has deteriorated sharply over the past four months.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
Ratings chart - Surperformance
Sector: Healthcare Facilities & Services
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| -8.68% | 2.47B | - | ||
| -17.89% | 8.36B | B+ | ||
| +39.20% | 3.6B | C+ | ||
| -39.11% | 2.73B | B- | ||
| -7.35% | 2.32B | B- | ||
| -12.61% | 1.77B | C- | ||
| -19.01% | 1.55B | A- | ||
| -40.66% | 1.22B | C+ | ||
| +7.56% | 1.09B | B+ | ||
| -15.34% | 1.03B | - | - |
Investor Rating
Trading Rating
ESG Refinitiv
-
Financials
Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
Valuation
P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
-
Divergence of Target Price
Earnings quality
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- SYAB Stock
- SYAB Stock
- Ratings SYNLAB AG
